Vector Science and Therapeutics (TSXV:PAIN) Interest Expense: C$-0.05 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PAIN Vector Science and Therapeutics Corp TSXV:PAIN
14 GF Score
Price C$1.55
View Full Analysis

What is Vector Science and Therapeutics Interest Expense?

Vector Science and Therapeutics TSXV:PAIN -4.32% 14 Interest Expense is C$-0.05 Mil as of Feb. 2026. GuruFocus rates TSXV:PAIN with a GF Score™ of 14/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vector Science and Therapeutics's interest expense for the three months ended in Feb. 2026 was C$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2026 was C$-0.05 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vector Science and Therapeutics's Operating Income for the three months ended in Feb. 2026 was C$ -0.42 Mil. Vector Science and Therapeutics's Interest Expense for the three months ended in Feb. 2026 was C$ 0.00 Mil. Vector Science and Therapeutics has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Vector Science and Therapeutics  (TSXV:PAIN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vector Science and Therapeutics's Interest Expense for the three months ended in Feb. 2026 was C$0.00 Mil. Its Operating Income for the three months ended in Feb. 2026 was C$-0.42 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Feb. 2026 was C$0.00 Mil.

Vector Science and Therapeutics's Interest Coverage for the quarter that ended in Feb. 2026 is calculated as

Vector Science and Therapeutics had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Vector Science and Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Vector Science and Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vector Science and Therapeutics Interest Expense Chart

Vector Science and Therapeutics Annual Data
Trend Aug24 Aug25
Interest Expense
0.00 -0.12

Vector Science and Therapeutics Quarterly Data
Aug24 Nov24 Aug25 Nov25 Feb26
Interest Expense 0.00 0.00 0.00 -0.05 0.00
TSXV:PAIN
14GF Score
Vector Science and Therapeutics Corp TSXV:PAIN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vector Science and Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of C$-0.05 Mil mean?
Vector Science and Therapeutics (TSXV:PAIN) has a Interest Expense of C$-0.05 Mil as of Feb. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Vector Science and Therapeutics and its competitors.
Is Vector Science and Therapeutics' Interest Expense too high?
Vector Science and Therapeutics' current Interest Expense is C$-0.05 Mil. Overall, Vector Science and Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' Interest Expense compare to ABT and SYK?
Vector Science and Therapeutics' Interest Expense of C$-0.05 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Vector Science and Therapeutics and its competitors. Vector Science and Therapeutics's current Interest Expense is C$-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current Interest Expense of C$-0.05 Mil. The current Interest Expense is C$-0.05 Mil. Vector Science and Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current Interest Expense is C$-0.05 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vector Science and Therapeutics Business Description

Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
14GF Score

Get the complete analysis for TSXV:PAIN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.55
Price